Health Occupations, Public Health, and Insurance - Menopause - Provider Training Coverage Requirements, Policy Initiatives, and Access to Care
SB 892 is a menopause-focused health policy bill that makes changes across Maryland’s health, insurance, and public health laws. It expands the State Advisory Council on Health and Wellness by adding the executive director of the Maryland Commission for Women and a member with expertise in perimenopausal, menopausal, and postmenopausal evaluation and treatment. The bill also directs the Maryland Department of Health to identify at least one approved training program on menopause care, in consultation with professional associations such as the Menopause Society.
The bill requires health occupations boards that mandate continuing education for license or certificate renewal to award at least two hours of continuing education credit for every hour completed on perimenopausal, menopausal, and postmenopausal evaluation and treatment, with authority to cap the total credits by regulation. It also requires insurers, nonprofit health service plans, and health maintenance organizations to cover the evaluation and management of menopause and menopause-associated symptoms as determined by the treating provider, and it applies to policies and contracts issued, delivered, or renewed on or after January 1, 2027.
In addition to the coverage mandate, SB 892 directs several state entities to study and report on broader menopause-related policy issues. The Maryland Health Care Commission must evaluate coverage barriers, including hormone replacement therapy and utilization management tools such as prior authorization and step therapy. The Maryland Commission for Women must assess policy initiatives that improve the health and economic security of people with perimenopausal, menopausal, and postmenopausal conditions, and the Maryland Department of Health must develop an action plan to expand access through community health workers and evaluate ways to increase clinical education opportunities, including postgraduate training.
The bill’s overall impact is to create new statutory requirements for provider education and insurance coverage while also launching state-level studies and recommendations on menopause care access. It affects health occupations boards, insurers, HMOs, the Maryland Department of Health, the Maryland Health Care Commission, and the Maryland Commission for Women, and it is intended to improve diagnosis, treatment, and access to menopause-related care across the state.
The general sentiment around SB 892 appears strongly favorable. The bill passed the Senate 41-0 and the House 130-2, indicating broad bipartisan support and little recorded opposition. No committee transcript was provided, but the voting history suggests the measure was viewed as a practical health access and women’s health initiative rather than a controversial policy change.
The main points of contention, to the extent they can be inferred from the bill text, are likely administrative and cost-related rather than ideological. Potential concerns include the insurance coverage mandate, the continuing education credit requirement for multiple licensing boards, and the added reporting and planning duties for state agencies. The bill also gives boards discretion to set maximum credit limits, which may reflect an effort to balance expanded training incentives with regulatory flexibility.
SB 892 amends the Health – General, Health Occupations, and Insurance articles of the Maryland Code. It expands the State Advisory Council on Health and Wellness, creates a new continuing education credit requirement for health occupations boards covering menopause-related training, requires the Department of Health to identify an approved training program, and mandates insurance coverage for menopause evaluation and management. It also directs the Maryland Health Care Commission, Maryland Commission for Women, and Maryland Department of Health to study barriers, policy options, community health worker outreach, and clinical education opportunities, with multiple reports due in 2026 and 2027.
The bill appears to have been received very positively. It passed both chambers overwhelmingly, with a unanimous Senate vote and only two no votes in the House. That voting pattern suggests broad support for improving menopause care, provider education, and insurance coverage, with no significant public opposition reflected in the available materials.
No committee testimony or floor debate is provided, so specific objections are not documented. Based on the bill’s structure, the most likely areas of concern are the new insurance coverage mandate, possible premium or utilization-management impacts, and the administrative burden on licensing boards and state agencies. The bill addresses these by allowing boards to set maximum continuing education credit limits and by using study/report provisions for several implementation questions, which suggests the legislature sought to balance access goals with regulatory flexibility.